Growing Use of Bispecifics for the Treatment of Multiple Myeloma
George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.
George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.
The FDA has approved one of the first human papillomavirus self-collection solutions for use in the US.
The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous…
In this episode of Targeted Talks, Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology.
A US health care executive survey found 30% see health equity solely as a social concern. Yet, it’s about ensuring everyone has a fair shot…
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment…
Due to federal budget constraints, the National Cancer Institute faces significant risk, impacting cancer research funding amid crucial breakthroughs.
The Oncologic Drug Advisory Committee of the FDA found that imetelstat has robust data supporting its use for transfusion-dependent anemia in patients with myelodysplastic syndromes.
Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.
With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in relapsed/refractory B-cell non-Hodgkin lymphomas will…
During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic…